The aim of this study was to determine the effectiveness of intratumoral injection of chemotherapeutics in improving the quality of life and survival of patients with pancreatic carcinoma.Patient concerns:
We present a case series of 5 patients with unresectable pancreatic adenocarcinoma.Diagnoses:
Patients diagnosed with unresectable poorly differentiated pancreatic ductal adenocarcinoma by intraoperative frozen biopsyor percutaneous biopsy.Interventions:
Five patients with unresectable pancreatic adenocarcinoma received a computed tomography-guided percutaneous intratumoral injection of gemcitabine plus cisplatin mixed with fibrin glue.Outcomes:
Mean overall survival was 16.2 ± 3.7 months. Local control rates were 100% and 80% at postoperative 3 and 6 months, respectively. Mean Visual Analogue Scale pain score decreased from 7.2 ± .84 preoperatively to 2 ± 1.22 at postoperative 4 weeks. There were no complications associated with the procedure.Lessons:
Percutaneous intratumoral injection of gemcitabine plus cisplatin mixed with fibrin glue for advanced pancreatic may be safe and effective.